Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
259
datasets available to search
ShareScore release 0.9.0
Dataset results
259 results for “hypertrophic cardiomyopathy”
Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
ClinicalTrials.gov study NCT06856265. IPD Sharing: NO. Countries: 0. Publications: 0.
Sexual Dimorphism in Cardiac Transcriptome Associated with a Troponin C Murine Model of Hypertrophic Cardiomyopathy
GEO Series GSE144098. Mus musculus. 16 samples. Type: Expression profiling by high throughput sequencing.
Microarray Analysis of a Familial Hypertrophic Cardiomyopathy Mouse Model Rescued by a Phospholamban Knockout
GEO Series GSE42892. Mus musculus. 24 samples. Type: Expression profiling by array.
Efficient in vivo Genome Editing Prevents Hypertrophic Cardiomyopathy in Mice [Amplified_cDNA]
GEO Series GSE220811. Mus musculus. 78 samples. Type: Expression profiling by high throughput sequencing.
Microarray Profiling of Long Non-coding RNA (lncRNA) Associated with Hypertrophic Cardiomyopathy
GEO Series GSE68316. Homo sapiens. 12 samples. Type: Expression profiling by array; Non-coding RNA profiling by array.
Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice [genomicDNA]
GEO Series GSE220850. Mus musculus. 245 samples. Type: Other.
Beneficial Effects of High Intensity Interval Training in a Mouse Model of Hypertrophic Cardiomyopathy
GEO Series GSE297707. Mus musculus. 64 samples. Type: Expression profiling by high throughput sequencing.
Beta-Adrenergic Stimulation and MYH7 G256E Mutant Gene Dosage Drive Hypertrophic Cardiomyopathy Phenotype Penetrance
GEO Series GSE276210. Homo sapiens. 14 samples. Type: Expression profiling by high throughput sequencing.
Differential gene expressions in the heart of hypertrophic cardiomyopathy patients
GEO Series GSE89714. Homo sapiens. 9 samples. Type: Expression profiling by high throughput sequencing.
MicroRNA Profiling of Surgical Myectomy Tissue from Patients with Hypertrophic Cardiomyopathy
GEO Series GSE36946. Homo sapiens. 127 samples. Type: Non-coding RNA profiling by array.
Transcriptome Profiling of Surgical Myectomy Tissue from Patients with Hypertrophic Cardiomyopathy
GEO Series GSE36961. Homo sapiens. 145 samples. Type: Expression profiling by array.
Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure
GEO Series GSE37692. Mus musculus. 12 samples. Type: Expression profiling by RT-PCR; Non-coding RNA profiling by array.
Analysis of microRNA expression profiles and prediction of target gene signaling pathways in familial hypertrophic cardiomyopathy with myosin-binding protein C3 (MYBPC3) gene mutations
GEO Series GSE150078. Homo sapiens. 6 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Human iPSC-derived cardiomyocyte from a patient with dilated phase of hypertrophic cardiomyopathy
GEO Series GSE263980. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Next generation mRNA and miRNA sequencing data sets from young and adult female and male healthy cats, and female and male adult cats with hypertrophic cardiomyopathy (HCM).
GEO Series GSE275971. Felis catus. 142 samples. Type: Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing.
RNA-sequencing of patients with hypertrophic cardiomyopathy or patients with aortic stenosis compared to heart healthy donors
GEO Series GSE230585. Homo sapiens. 16 samples. Type: Expression profiling by high throughput sequencing.
Candidacy and long-term outcomes of subcutaneous implantable cardioverter-defibrillators in current practice in patients with Hypertrophic Cardiomyopathy
<p>Dataset associated with paper "Candidacy and long-term outcomes of subcutaneous implantable cardioverter-defibrillators in current practice in patients with Hypertrophic Cardiomyopathy"</p> <p><strong>This set of raw data is accessible under request because include sensitive information. Please write your request at l.crotti@auxologico.it</strong></p>
Partial Dataset related to the article: The prognostic role of right ventricular dysfunction in patients with hypertrophic cardiomyopathy
<p>This record contain partial raw data related to the article: The prognostic role of right ventricular dysfunction in patients with hypertrophic cardiomyopathy</p> <p>Hypertrophic cardiomyopathy (HCM) primarily affects the left ventricle (LV) sparing the right ventricle (RV) in vast majority of cases. However, several studies employing CMR have revealed that myocardial hypertrophy may also involve the RV. To assess RV size and function in a large prospectively cohort of HCM patients and to evaluate whether these parameters in association with other MR findings can predict cardiac events. Two participating centers prospectively included patients with known or suspected HCM between 2011 and 2017. CMR studies were performed with three different scanners. Outcome measures were a composite of ventricular arrhythmias, hospitalization for HF and cardiac death. Of 607 consecutive patients with known or suspected HCM, 315 had complete follow-up information (mean 65 ± 20 months). Among them, 115 patients developed major cardiac events (MACE) during follow-up. At CMR evaluation, patients with events had higher left atrium (LA) diameter (41.5 ± 8 mm vs. 37.17 ± 7.6 mm, p < 0.0001), LV mass (156.7 vs. 144 g, p = 0.005) and myocardial LGE (4.3% vs. 1.9%, p = 0.001). Similarly, patients with events had lower RV stroke volume index (42.7 vs. 47.0, p = 0.0003) and higher prevalence of both RV hypertrophy (16.4% vs. 4.7%, p = 0.0005) and reduced RV ejection fraction (12.2% vs. 4.4%, p = 0.006). In the multivariate analysis, LA diameter and RV stroke volume index were the strongest predictors of events (p < 0.001 and p = 0.0006, respectively). Anatomic and functional RV anomalies detected and characterized with CMR may have may have a major role in predicting the prognosis of HCM patients.</p>
Dataset related to the publication "Mapelli M, Romani S, Magri D, Merlo M, Cittar M, Mase M, et al. Exercise oxygen pulse kinetics in patients with hypertrophic cardiomyopathy". Heart.
<p><strong>Objectives: </strong>Reduced cardiac output (CO) has been considered crucial in symptoms' genesis in hypertrophic cardiomyopathy (HCM). Absolute value and temporal behaviour of O<sub>2</sub>-pulse (oxygen uptake/heart rate (VO<sub>2</sub>/HR)), and the VO<sub>2</sub>/work relationship during exercise reflect closely stroke volume (SV) and CO changes, respectively. We hypothesise that adding O<sub>2</sub>-pulse absolute value and kinetics, and VO<sub>2</sub>/work relationship to standard cardiopulmonary exercise testing (CPET) could help identify more exercise-limited patients with HCM.</p> <p><strong>Methods: </strong>CPETs were performed in 3 HCM dedicated clinical units. We retrospectively enrolled non-end-stage consecutive patients with HCM, grouped according to left ventricle outflow tract obstruction (LVOTO) at rest or during Valsalva manoeuvre (72% of patients with LVOTO <30; 10% between 30 and 49 and 18% ≥50 mm Hg). We evaluated the CPET response in HCM focusing on parameters strongly associated with SV and CO, such as O<sub>2</sub>-pulse and VO<sub>2</sub>, respectively, considering their absolute values and temporal behaviour during exercise.</p> <p><strong>Results: </strong>We included 312 patients (70% males, age 49±18 years). Peak VO<sub>2</sub> (percentage of predicted), O<sub>2</sub>-pulse and ventilation to carbon dioxide production (VE/VCO<sub>2</sub>) slope did not change across LVOTO groups. Ninety-six (31%) patients with HCM presented an abnormal O<sub>2</sub>-pulse temporal behaviour, irrespective of LVOTO values. These patients showed lower peak systolic pressure, workload (106±45 vs 130±49 W), VO<sub>2</sub> (21.3±6.6 vs 24.1±7.7 mL/min/kg; 74%±17% vs 80%±20%) and O<sub>2</sub>-pulse (12 (9-14) vs 14 (11-17) mL/beat), with higher VE/VCO<sub>2</sub> slope (28 (25-31) vs 27 (24-31)) (p<0.005 for all). Only 2 patients had an abnormal VO<sub>2</sub>/work slope.</p> <p><strong>Conclusion: </strong>None of the frequently used CPET parameters, either as absolute values or dynamic relationships, were associated with LVOTO. Differently, an abnormal temporal behaviour of O<sub>2</sub>-pulse during exercise, which is strongly related to inadequate SV increase, correlates with reduced functional capacity (peak and anaerobic threshold VO<sub>2</sub> and workload) and increased VE/VCO<sub>2</sub> slope, identifying more advanced disease irrespectively of LVOTO.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.